European Journal of Preventive Cardiology and secondary cardiovascular prevention and sport cardiology. It publishes 18 issues yearly and abstracted and indexed in Scopus and the Social Sciences Citation Index. According to the "Journal Citation Reports", its 2016 impact factor is 3.6, ranking it 43th out of 125 journals in the category "Cardiac & Cardiovascular Systems". Areas of interests are Cardiovascular primary and secondary preventions, (including arterial hypertension, dyslipidaemia, diabetes, obesity, smoking cessation, healthy life style promotion), epidemiology, cardiac rehabilitation, exercise training and physiology, sport cardiology, population science intervention. European Journal of Preventive Cardiology The European Journal of Preventive Cardiology is a peer-reviewed medical journal that
Cardiovascular disease in Australia enzyme which accelerates the development of diabetic atherosclerosis. Researchers were able to substantially reduce the development of artery plaques by suppressing or inhibiting this enzyme with a new drug, which will allow prevention and treatment of cardiovascular disease in people with diabetes. Another team, led by Bronwyn Kingwell, Head of the Baker Institute's Metabolic and Vascular Physiology, have found a new use for an old drug. The researchers found that after taking the standard anti-hypertensive drug Ramipril, patients with peripheral arterial disease (PAD), which restricts mobility due to leg pain, enjoyed a longer and less painful time on their feet.